Among the drugs used for MS, few like IFN-beta, Natalizumab, Glatiramer acetate don't cross BBB while Fingolimod do. So a humble request to the experts for their comments.
There is a hypothetical target, a subgroup of
B lymphocytes (David Hafler, Kevin O Connor
et al.) which ripen in the lymph nodes of
the cervix. They can be fought outside
the central nervous system.
https://www.ncbi.nlm.nih.gov/pubmed/25100741
Regards,
Joachim
In view of the venous changes given in MS only, it would be required for a drug to be effective in multiple sclerosis to prevent the retrograde damaging of particular branches of the internal cerebral veins - something obviously not being required in ADEM/EAE
i dont think BBB cross is important as the main concern is the immune system
http://www.asianscientist.com/2015/09/in-the-lab/crossing-blood-brain-barrier/
You can refer to this paper
It might be helpful
Amr Hassan
- Badges
- Science topic